Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085891
Status:
COMPLETED
Last Update Posted:
2009-03-25
First Post:
2004-06-16
Brief Title:
Efficacy Safety of Quetiapine Fumarate SEROQUEL Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 6-Week Multicenter Double-Blind Double-Dummy Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate SEROQUEL and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None